Ipsen is voluntarily removing its cancer therapy Tazverik from the U.S. market due to safety concerns. An ongoing clinical trial reported secondary hematologic malignancies, serious blood cancers, suggesting that the risks may outweigh potential benefits for patients.
Tazverik received accelerated approval from the FDA in 2020 to treat epithelioid sarcoma, a rare soft tissue cancer, and relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma. The voluntary withdrawal applies to all approved indications.
Resource: Cancer drug pulled from US market